在ROS1-重排序的高级非小细胞肺癌中治疗选择
Brigida Stanzione1, Alessandro Del Conte1, Elisa Bertoli1,2
1Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
非小细胞肺癌 (NSCLC) 中的ROS1重组对向治疗有反应. 新的氨酸激酶抑制剂 (TKIs) 为ROS1阳性NSCLC患者提供了改善的功效和中枢神经系统活性,解决了耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在0.9-2.6%的非小细胞肺癌 (NSCLC) 病例中发现了ROS原基因1 (ROS1) 的重组.
- 这些重组预测了对特定的氨酸激酶抑制剂 (TKI) 的敏感性.
研究的目的:
- 审查ROS1阳性NSCLC的临床病理学特征.
- 总结ROS1阳性NSCLC的当前和新兴治疗策略.
主要方法:
- 对ROS1-阳性NSCLC的临床试验和研究的文献综述.
- 已批准和正在研究的技术知识产权的有效性和耐药性机制的分析.
主要成果:
- 第一代TKIcrizotinib是ROS1阳性NSCLC的最初向治疗方法.
- 恩特雷克提尼布是一种强大的多位抑制剂,具有增强的中枢神经系统活性,现在已被批准用于未经治疗的患者.
- 对TKI的耐药性可以在平均5.5-20个月后出现,需要新的治疗方法.
结论:
- 具有ROS1阳性的NSCLC具有独特的临床病理特征和治疗脆弱性.
- 开发下一代具有增强功效和大脑透性的TKI对于克服耐药性和改善患者治疗结果至关重要.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment Resistant Cancers
